Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis. Annals of surgical oncology Sahara, K. n., Tsilimigras, D. I., Mehta, R. n., Moro, A. n., Paredes, A. Z., Lopez-Aguiar, A. G., Rocha, F. n., Kanji, Z. n., Weber, S. n., Fisher, A. n., Fields, R. n., Krasnick, B. A., Idrees, K. n., Smith, P. M., Poultsides, G. A., Makris, E. n., Cho, C. n., Beems, M. n., Dillhoff, M. n., Maithel, S. K., Endo, I. n., Pawlik, T. M. 2019

Abstract

The role of routine lymphadenectomy in the surgical treatment of pancreatic neuroendocrine tumors (pNET) remains poorly defined. The objective of the current study was to investigate trends in the number of lymph nodes (LN) evaluated for pNET treatment at a nationwide level.Patients undergoing surgery for pNET between 2000 and 2016 were identified in the U.S. Neuroendocrine Tumor Study Group (US-NETSG) database as well as the Surveillance, Epidemiology, and End Results (SEER) database. The number of LNs examined was evaluated over time.The median number of evaluated LNs increased roughly fourfold over the study period (US-NETSG, 2000: 3 LNs vs. 2016: 13 LNs; SEER, 2000: 3 LNs vs. 2016: 11 LNs, both p??2 cm were associated with 12 or more LNs evaluated in both US-NETSG and SEER databases.The number of LNs examined nearly quadrupled over the last decade. The increased number of LNs examined suggested a growing adoption of the AJCC staging manual recommendations regarding LN evaluation in the treatment of pNET.

View details for DOI 10.1245/s10434-019-08120-1

View details for PubMedID 31838609